These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

399 related articles for article (PubMed ID: 11112019)

  • 21. Pharmacokinetics and protein binding of mycophenolic acid in stable lung transplant recipients.
    Ensom MH; Partovi N; Decarie D; Dumont RJ; Fradet G; Levy RD
    Ther Drug Monit; 2002 Apr; 24(2):310-4. PubMed ID: 11897977
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Population pharmacokinetics of mycophenolic acid : a comparison between enteric-coated mycophenolate sodium and mycophenolate mofetil in renal transplant recipients.
    de Winter BC; van Gelder T; Glander P; Cattaneo D; Tedesco-Silva H; Neumann I; Hilbrands L; van Hest RM; Pescovitz MD; Budde K; Mathot RA
    Clin Pharmacokinet; 2008; 47(12):827-38. PubMed ID: 19026038
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Differences in clearance of mycophenolic acid among renal transplant recipients, hematopoietic stem cell transplant recipients, and patients with autoimmune disease.
    de Winter BC; Mathot RA; Sombogaard F; Neumann I; van Hest RM; Doorduijn JK; van Gelder T
    Ther Drug Monit; 2010 Oct; 32(5):606-14. PubMed ID: 20720518
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of cyclosporine on mycophenolic acid area under the concentration-time curve in pediatric kidney transplant recipients.
    Filler G; Lepage N; Delisle B; Mai I
    Ther Drug Monit; 2001 Oct; 23(5):514-9. PubMed ID: 11591896
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacokinetics of mycophenolate mofetil in stable pediatric liver transplant recipients receiving mycophenolate mofetil and cyclosporine.
    Lobritto SJ; Rosenthal P; Bouw R; Leung M; Snell P; Mamelok RD
    Liver Transpl; 2007 Nov; 13(11):1570-5. PubMed ID: 17969194
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Atypical pharmacokinetics and metabolism of mycophenolic acid in a young kidney transplant recipient with impaired renal function.
    Wigger M; Armstrong VW; Shipkova M; Wacke R; Nizze H; Streit F; von Ahsen N; Muscheites J; Glasenapp S; Stolpe HJ; Oellerich M
    Ther Drug Monit; 2002 Jun; 24(3):438-43. PubMed ID: 12021639
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Correlation of IMPDH1 gene polymorphisms with subclinical acute rejection and mycophenolic acid exposure parameters on day 28 after renal transplantation.
    Kagaya H; Miura M; Saito M; Habuchi T; Satoh S
    Basic Clin Pharmacol Toxicol; 2010 Aug; 107(2):631-6. PubMed ID: 20136638
    [TBL] [Abstract][Full Text] [Related]  

  • 28. High interpatient variability in response to mycophenolic acid maintenance therapy in patients with ANCA-associated vasculitis.
    Schaier M; Scholl C; Scharpf D; Schmitt WH; Schwenger V; Zeier M; Sommerer C
    Nephrol Dial Transplant; 2015 Apr; 30 Suppl 1():i138-45. PubMed ID: 25805745
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Plasma and intracellular pharmacokinetic-pharmacodynamic analysis of mycophenolic acid in de novo kidney transplant patients.
    Thi MT; Mourad M; Capron A; Tshinanu FM; Vincent MF; Wallemacq P
    Clin Biochem; 2015 Apr; 48(6):401-5. PubMed ID: 25523299
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical pharmacokinetics of mycophenolate mofetil.
    Bullingham RE; Nicholls AJ; Kamm BR
    Clin Pharmacokinet; 1998 Jun; 34(6):429-55. PubMed ID: 9646007
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacokinetic and pharmacodynamic analysis of enteric-coated mycophenolate sodium: limited sampling strategies and clinical outcome in renal transplant patients.
    Sommerer C; Müller-Krebs S; Schaier M; Glander P; Budde K; Schwenger V; Mikus G; Zeier M
    Br J Clin Pharmacol; 2010 Apr; 69(4):346-57. PubMed ID: 20406219
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Area under the plasma concentration-time curve for total, but not for free, mycophenolic acid increases in the stable phase after renal transplantation: a longitudinal study in pediatric patients. German Study Group on Mycophenolate Mofetil Therapy in Pediatric Renal Transplant Recipients.
    Weber LT; Lamersdorf T; Shipkova M; Niedmann PD; Wiesel M; Zimmerhackl LB; Staskewitz A; Schütz E; Mehls O; Oellerich M; Armstrong VW; Tönshoff B
    Ther Drug Monit; 1999 Oct; 21(5):498-506. PubMed ID: 10519445
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Mycophenolate, clinical pharmacokinetics, formulations, and methods for assessing drug exposure.
    Tett SE; Saint-Marcoux F; Staatz CE; Brunet M; Vinks AA; Miura M; Marquet P; Kuypers DR; van Gelder T; Cattaneo D
    Transplant Rev (Orlando); 2011 Apr; 25(2):47-57. PubMed ID: 21190834
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Inosine monophosphate dehydrogenase (IMPDH) activity as a pharmacodynamic biomarker of mycophenolic acid effects in pediatric kidney transplant recipients.
    Fukuda T; Goebel J; Thøgersen H; Maseck D; Cox S; Logan B; Sherbotie J; Seikaly M; Vinks AA
    J Clin Pharmacol; 2011 Mar; 51(3):309-20. PubMed ID: 20418509
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pharmacokinetic basis for the efficient and safe use of low-dose mycophenolate mofetil in combination with tacrolimus in kidney transplantation.
    Mourad M; Malaise J; Chaib Eddour D; De Meyer M; König J; Schepers R; Squifflet JP; Wallemacq P
    Clin Chem; 2001; 47(7):1241-8. PubMed ID: 11427455
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Evaluation of inosin-5'-monophosphate dehydrogenase activity during maintenance therapy with tacrolimus.
    Maiguma T; Yosida T; Otsubo K; Okabe Y; Sugitani A; Tanaka M; Oishi R; Teshima D
    J Clin Pharm Ther; 2010 Feb; 35(1):79-85. PubMed ID: 20175815
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacokinetics of mycophenolic acid in kidney transplant recipients treated with a low dose (1 gram/day) of mycophenolate mofetil.
    Julasareekul W; Eiam-Ong S; Bejraputra O; Seublinvong T
    J Med Assoc Thai; 2003 Aug; 86(8):766-71. PubMed ID: 12948276
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Defining algorithms for efficient therapeutic drug monitoring of mycophenolate mofetil in heart transplant recipients.
    Kaczmarek I; Bigdeli AK; Vogeser M; Mueller T; Beiras-Fernandez A; Kaczmarek P; Schmoeckel M; Meiser B; Reichart B; Ueberfuhr P
    Ther Drug Monit; 2008 Aug; 30(4):419-27. PubMed ID: 18641552
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A randomized double-blind, multicenter plasma concentration controlled study of the safety and efficacy of oral mycophenolate mofetil for the prevention of acute rejection after kidney transplantation.
    van Gelder T; Hilbrands LB; Vanrenterghem Y; Weimar W; de Fijter JW; Squifflet JP; Hené RJ; Verpooten GA; Navarro MT; Hale MD; Nicholls AJ
    Transplantation; 1999 Jul; 68(2):261-6. PubMed ID: 10440399
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacokinetic and pharmacodynamic comparison of enteric-coated mycophenolate sodium and mycophenolate mofetil in maintenance renal transplant patients.
    Budde K; Bauer S; Hambach P; Hahn U; Röblitz H; Mai I; Diekmann F; Neumayer HH; Glander P
    Am J Transplant; 2007 Apr; 7(4):888-98. PubMed ID: 17391132
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.